Literature DB >> 15040181

Where will new antibiotics come from?

Christopher Walsh1.   

Abstract

There is a constant need for new antibacterial drugs owing to the inevitable development of resistance that follows the introduction of antibiotics to the clinic. When a new class of antibiotic is introduced, it is effective at first, but will eventually select for survival of the small fraction of bacterial populations that have an intrinsic or acquired resistance mechanism. Pathogens that are resistant to multiple drugs emerge around the globe, so how robust are antibiotic discovery processes?

Mesh:

Substances:

Year:  2003        PMID: 15040181     DOI: 10.1038/nrmicro727

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  191 in total

1.  Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: New design with improved properties.

Authors:  Genbin Shi; Gary Shaw; Yu-He Liang; Priadarsini Subburaman; Yue Li; Yan Wu; Honggao Yan; Xinhua Ji
Journal:  Bioorg Med Chem       Date:  2011-11-23       Impact factor: 3.641

2.  Identification and characterization of the anti-methicillin-resistant Staphylococcus aureus WAP-8294A2 biosynthetic gene cluster from Lysobacter enzymogenes OH11.

Authors:  Wei Zhang; Yaoyao Li; Guoliang Qian; Yan Wang; Haotong Chen; Yue-Zhong Li; Fengquan Liu; Yuemao Shen; Liangcheng Du
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

3.  An antibody as surrogate receptor reveals determinants of activity of an innate immune peptide antibiotic.

Authors:  Suvendu Lomash; Sushma Nagpal; Dinakar M Salunke
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

4.  Grand challenge commentary: Exploiting single-cell variation for new antibiotics.

Authors:  Erick Strauss
Journal:  Nat Chem Biol       Date:  2010-12       Impact factor: 15.040

5.  A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents.

Authors:  Charles A Testa; L Jeffrey Johnson
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

6.  Bisubstrate analog inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: new lead exhibits a distinct binding mode.

Authors:  Genbin Shi; Gary Shaw; Yue Li; Yan Wu; Honggao Yan; Xinhua Ji
Journal:  Bioorg Med Chem       Date:  2012-06-06       Impact factor: 3.641

7.  Biophysical Studies of Bacterial Topoisomerases Substantiate Their Binding Modes to an Inhibitor.

Authors:  CongBao Kang; Yan Li; Joseph Cherian; Boping Liu; Hui Qi Ng; Michelle Yueqi Lee; Nur Huda Binte Ahmad; Zhi Ying Poh; Yun Xuan Wong; Qiwei Huang; Ying Lei Wong; Alvin W Hung; Jeffrey Hill; Thomas H Keller
Journal:  Biophys J       Date:  2015-11-03       Impact factor: 4.033

8.  Staphylococcus aureus virulence attenuation and immune clearance mediated by a phage lysin-derived protein.

Authors:  Hang Yang; Jingjing Xu; Wuyou Li; Shujuan Wang; Junhua Li; Junping Yu; Yuhong Li; Hongping Wei
Journal:  EMBO J       Date:  2018-07-23       Impact factor: 11.598

9.  Bioinformatics and Molecular Biological Characterization of a Hypothetical Protein SAV1226 as a Potential Drug Target for Methicillin/Vancomycin-Staphylococcus aureus Infections.

Authors:  Nichole Haag; Kimberly Velk; Tyler McCune; Chun Wu
Journal:  World Acad Sci Eng Technol       Date:  2015-06

10.  Activity of the novel peptide arminin against multiresistant human pathogens shows the considerable potential of phylogenetically ancient organisms as drug sources.

Authors:  René Augustin; Friederike Anton-Erxleben; Stephanie Jungnickel; Georg Hemmrich; Björn Spudy; Rainer Podschun; Thomas C G Bosch
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.